+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030- Product Image
Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030- Product Image
Sale

Cancer Supportive Care Drugs Market by Drug Class, Indication, Distribution Channel, End User, Route Of Administration - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010628
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Supportive Care Drugs Market is evolving rapidly, driven by advancements in therapy usage, strategic partnerships, and the increasing focus on patient-centered oncology care. Senior decision-makers require clear insights into market segmentation, regional strategies, and supply chain influences to inform future investment and operational direction.

Market Snapshot: Cancer Supportive Care Drugs Market

Between 2024 and 2025, the Cancer Supportive Care Drugs Market expanded from USD 21.46 billion to USD 22.46 billion, and is projected to reach USD 28.07 billion by 2030, posting a CAGR of 4.57%. This growth reflects expanding use of supportive care products, including antiemetics, bone-modifying agents, and growth factors, as integral components in advanced oncology treatment regimens. Key regions including the Americas, EMEA, and Asia-Pacific are experiencing heightened demand, influenced by both innovation and regulatory developments.

Scope & Segmentation

This research offers comprehensive segmentation and analysis to help leadership teams and key stakeholders pinpoint growth opportunities across the cancer supportive care landscape.

  • Drug Class: Antiemetics (5-HT3 antagonists such as granisetron and ondansetron; NK1 antagonists including aprepitant), Bone-Modifying Agents (bisphosphonates like pamidronate, zoledronic acid, and RANKL inhibitors such as denosumab), Erythropoiesis Stimulating Agents (darbepoetin alfa, epoetin alfa), Growth Factors (filgrastim, pegfilgrastim), and Pain Management Agents (NSAIDs like diclofenac, opioids including fentanyl and morphine).
  • Indication: Includes bone metastases related events, cancer-related anemia (transfusion-dependent and non-transfusion-dependent), cancer-related pain (acute and chronic), chemotherapy-induced nausea and vomiting (acute and delayed), and chemotherapy-induced neutropenia (febrile and non-febrile).
  • Distribution Channel: Covers hospital pharmacies (inpatient, outpatient), online pharmacies, retail, and specialty pharmacies.
  • End User: Encompasses clinics, home healthcare, and hospitals.
  • Route of Administration: Includes intravenous infusions, oral forms (capsules, tablets), and subcutaneous injections.
  • Regional Coverage: Americas (United States with key states like California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, UAE, Saudi Arabia, South Africa, and others), Asia-Pacific (key countries such as China, India, Japan, Australia, South Korea, and more).
  • Leading Companies: Amgen Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceuticals USA, Inc., Viatris Inc., and Fresenius Kabi AG.

Key Takeaways for Decision-Makers

  • Supportive care therapies are now fundamental to cancer regimens, directly enhancing patient outcomes and adherence to treatment protocols.
  • Introduction of new drug classes and digital health solutions supports earlier intervention and safer patient management throughout the treatment pathway.
  • Regulatory adaptation and value-based contracting models are shaping product launches and reimbursement strategies, driving a greater focus on real-world evidence.
  • Strategic collaborations between innovators and contract manufacturing organizations are facilitating scale-up and access to new formulations.
  • Stakeholders in both high- and middle-income countries are leveraging public-private partnerships, digital health solutions, and regional manufacturing to improve access and control costs.

Tariff Impact: Navigating Pricing and Supply Chain Pressures

Tariff Pressures in Cancer Supportive Care Drugs

United States pharmaceutical tariffs introduced in 2025 have increased production costs for manufacturers reliant on imported raw materials and finished drugs, with logistically complex supply chains experiencing downstream effects on pricing and rebate agreements. In response, some organizations have localized manufacturing to bolster resilience, shifting supplier strategies and strengthening procurement platforms. These adjustments favor established manufacturers and encourage partnerships with biotech startups for competitive advantage.

Methodology & Data Sources

The Cancer Supportive Care Drugs Market analysis utilizes a two-stage methodology: comprehensive secondary research—including industry reports, regulatory filings, and peer-reviewed journals—supplemented by targeted primary interviews with oncologists, pharmacists, and policy experts. Findings were validated using case studies and advanced qualitative analytics for robust, bias-mitigated insights supporting senior-level decisions.

Why This Report Matters

  • Equips executives with granular segmentation and regional market intelligence to inform expansion and portfolio investment plans.
  • Clarifies disruptive influences such as tariff shifts, digital health adoption, and precision medicine, helping organizations anticipate risks and competitive movements.
  • Focuses on actionable recommendations to strengthen supply chain resilience and optimize commercial strategies in complex market conditions.

Conclusion

This report provides actionable, evidence-based intelligence on the cancer supportive care landscape. Strategic planning, technology integration, and tailored market access will shape tomorrow’s competitive leaders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Accelerated approval of long-acting G-CSF biosimilars enhancing neutropenia management in chemotherapy
5.2. Integration of digital health platforms to monitor and improve patient adherence to supportive care regimens
5.3. Expanding use of pharmacogenomic testing to personalize antiemetic and analgesic supportive care therapies
5.4. Clinical development of oral selective NK-1 receptor antagonists for multidrug chemotherapy-induced nausea relief
5.5. Adoption of inhaled and transdermal formulations to mitigate chemotherapy-induced mucositis and mucosal toxicity
5.6. Growing market competition from generic and biosimilar pegfilgrastim alternatives reducing treatment costs
5.7. Emerging cannabinoid-based supportive therapies targeting refractory cancer pain and chemotherapy side effects
5.8. Implementation of real-world evidence studies for reimbursement of high-cost supportive care biologics in oncology
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Supportive Care Drugs Market, by Drug Class
8.1. Introduction
8.2. Antiemetics
8.2.1. 5-HT3 Antagonists
8.2.1.1. Granisetron
8.2.1.2. Ondansetron
8.2.2. NK1 Antagonists
8.2.2.1. Aprepitant
8.3. Bone-Modifying Agents
8.3.1. Bisphosphonates
8.3.1.1. Pamidronate
8.3.1.2. Zoledronic Acid
8.3.2. RANKL Inhibitors
8.3.2.1. Denosumab
8.4. Erythropoiesis Stimulating Agents
8.4.1. Darbepoetin Alfa
8.4.2. Epoetin Alfa
8.5. Growth Factors
8.5.1. Filgrastim
8.5.2. Pegfilgrastim
8.6. Pain Management Agents
8.6.1. NSAIDs
8.6.1.1. Diclofenac
8.6.2. Opioids
8.6.2.1. Fentanyl
8.6.2.2. Morphine
9. Cancer Supportive Care Drugs Market, by Indication
9.1. Introduction
9.2. Bone Metastases Related Events
9.3. Cancer-Related Anemia
9.3.1. Non-Transfusion-Dependent
9.3.2. Transfusion-Dependent
9.4. Cancer-Related Pain
9.4.1. Acute Pain
9.4.2. Chronic Pain
9.5. Chemotherapy-Induced Nausea & Vomiting
9.5.1. Acute
9.5.2. Delayed
9.6. Chemotherapy-Induced Neutropenia
9.6.1. Febrile Neutropenia
9.6.2. Non-Febrile Neutropenia
10. Cancer Supportive Care Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Online Pharmacies
10.4. Retail Pharmacies
10.5. Specialty Pharmacies
11. Cancer Supportive Care Drugs Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Healthcare
11.4. Hospitals
12. Cancer Supportive Care Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Intravenous
12.3. Oral
12.3.1. Capsules
12.3.2. Tablets
12.4. Subcutaneous
13. Americas Cancer Supportive Care Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Supportive Care Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Amgen Inc.
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Johnson & Johnson
16.3.6. Sanofi S.A.
16.3.7. GlaxoSmithKline plc
16.3.8. Teva Pharmaceuticals USA, Inc.
16.3.9. Viatris Inc.
16.3.10. Fresenius Kabi AG
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHAI
FIGURE 26. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. CANCER SUPPORTIVE CARE DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APREPITANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APREPITANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAMIDRONATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAMIDRONATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DARBEPOETIN ALFA, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY EPOETIN ALFA, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FENTANYL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FENTANYL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MORPHINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY MORPHINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE METASTASES RELATED EVENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-TRANSFUSION-DEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-TRANSFUSION-DEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSFUSION-DEPENDENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TRANSFUSION-DEPENDENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ACUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DELAYED, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FEBRILE NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY FEBRILE NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-FEBRILE NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-FEBRILE NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 145. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 146. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 147. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 148. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 149. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 150. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 151. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 152. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 153. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 154. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2025-2030 (USD MILLION)
TABLE 183. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2024 (USD MILLION)
TABLE 184. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2025-2030 (USD MILLION)
TABLE 185. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
TABLE 186. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
TABLE 187. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 188. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 189. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 192. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 193. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 198. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 199. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 200. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
TABLE 221. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 222. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 223. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 224. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 225. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2024 (USD MILLION)
TABLE 228. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2025-2030 (USD MILLION)
TABLE 229. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2024 (USD MILLION)
TABLE 230. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2025-2030 (USD MILLION)
TABLE 231. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
TABLE 232. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
TABLE 233. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 234. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 235. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 238. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 239. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 244. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 245. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 246. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 247. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 248. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 249. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 250. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 251. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 252. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 253. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 254. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 255. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
TABLE 256. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2025-2030 (USD MILLION)
TABLE 257. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
TABLE 258. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, 2025-2030 (USD MILLION)
TABLE 259. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2018-2024 (USD MILLION)
TABLE 260. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY RANKL INHIBITORS, 2025-2030 (USD MILLION)
TABLE 261. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2018-2024 (USD MILLION)
TABLE 262. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, 2025-2030 (USD MILLION)
TABLE 263. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
TABLE 264. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GROWTH FACTORS, 2025-2030 (USD MILLION)
TABLE 265. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2018-2024 (USD MILLION)
TABLE 266. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PAIN MANAGEMENT AGENTS, 2025-2030 (USD MILLION)
TABLE 267. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
TABLE 268. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NSAIDS, 2025-2030 (USD MILLION)
TABLE 269. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2018-2024 (USD MILLION)
TABLE 270. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, 2025-2030 (USD MILLION)
TABLE 271. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2018-2024 (USD MILLION)
TABLE 274. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED ANEMIA, 2025-2030 (USD MILLION)
TABLE 275. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2018-2024 (USD MILLION)
TABLE 276. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CANCER-RELATED PAIN, 2025-2030 (USD MILLION)
TABLE 277. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2018-2024 (USD MILLION)
TABLE 278. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA & VOMITING, 2025-2030 (USD MILLION)
TABLE 279. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2018-2024 (USD MILLION)
TABLE 280. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, 2025-2030 (USD MILLION)
TABLE 281. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
TABLE 284. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2030 (USD MILLION)
TABLE 285. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 290. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 291. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 292. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 293. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2018-2024 (USD MILLION)
TABLE 294. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, 2025-2030 (USD MILLION)
TABLE 295. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 296. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY 5-HT3 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 297. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 298. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NK1 ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 299. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BONE-MODIFYING AGENTS, 2018-2024 (USD MILLION)
TABLE 300. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BO

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cancer Supportive Care Drugs market report include:
  • Amgen Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals USA, Inc.
  • Viatris Inc.
  • Fresenius Kabi AG

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 22.46 Billion
Forecasted Market Value ( USD ) by 2030 $ 28.07 Billion
Compound Annual Growth Rate4.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type (Supportive Care, Therapeutics), Route Of Administration (Intramuscular, Intravenous, Oral), Mechanism Of Action, Indication, Distribution Channel - Global Forecast 2025-2030 - Product Image

Cancer Therapeutics & Supportive Care Drugs Market by Drug Type (Supportive Care, Therapeutics), Route Of Administration (Intramuscular, Intravenous, Oral), Mechanism Of Action, Indication, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Cancer Supportive Care Drugs Market Report 2025 - Product Image

Cancer Supportive Care Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cancer Supportive Care Products Market Report 2025 - Product Image

Cancer Supportive Care Products Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Chemotherapy Induced Myelosuppression Treatment - Global Strategic Business Report - Product Image

Chemotherapy Induced Myelosuppression Treatment - Global Strategic Business Report

  • Report
  • 473 Pages
  • Global
From
Cancer Supportive Care Market 2024-2028 - Product Image

Cancer Supportive Care Market 2024-2028

  • Report
  • 188 Pages
  • Global
From

About the Cancer Care Market

The Cancer Care market within the context of Oncology Drugs is a rapidly growing industry. It is composed of a variety of products and services, including drugs, diagnostics, and treatments. Oncology drugs are used to treat cancer, and they can be divided into two categories: targeted therapies and immunotherapies. Targeted therapies are designed to target specific cancer cells, while immunotherapies are designed to boost the body's own immune system to fight cancer. Both types of drugs are used to treat a variety of cancers, including breast, lung, and colorectal cancer. The Cancer Care market is highly competitive, with many companies vying for market share. Companies in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. These companies are all involved in the development, manufacture, and marketing of oncology drugs. Additionally, there are many smaller companies that specialize in the development of new treatments and therapies. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.